Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Gain Therapeutics, Inc. (GANX) had Stock-Based Compensation of $2.39M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-20.41M |
|
-- |
|
-- |
|
$20.35M |
|
$-20.35M |
|
$0.48M |
|
$-19.87M |
|
$-19.87M |
|
$-20.41M |
|
$-20.41M |
|
$-20.41M |
|
$-20.41M |
|
$-20.35M |
|
$-20.27M |
|
22.88M |
|
22.88M |
|
$-0.89 |
|
$-0.89 |
|
| Balance Sheet Financials | |
$11.60M |
|
$0.10M |
|
$0.52M |
|
$12.12M |
|
$3.91M |
|
$0.33M |
|
$0.87M |
|
$4.78M |
|
$7.34M |
|
$7.34M |
|
$7.34M |
|
27.13M |
|
| Cash Flow Statement Financials | |
$-18.87M |
|
$4.98M |
|
$13.01M |
|
$11.83M |
|
$10.42M |
|
$-1.41M |
|
|
Stock-Based Compensation |
$2.39M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.97 |
|
-- |
|
-- |
|
0.04 |
|
0.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.90M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-278.10% |
|
-278.10% |
|
-168.36% |
|
-266.19% |
|
$0.27 |
|
$-0.83 |
|
$-0.82 |
|